Free Trial
→ Many investors are about to lose everything (From Porter & Company) (Ad)tc pixel Free TYRA Stock Alerts

Tyra Biosciences (TYRA) Financials

Tyra Biosciences logo
$21.00 -1.30 (-5.83%)
Closing price 04:00 PM Eastern
Extended Trading
$21.00 0.00 (-0.02%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Tyra Biosciences

Annual Income Statements for Tyra Biosciences

This table shows Tyra Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.34 -26 -55 -69 -86 -120
Consolidated Net Income / (Loss)		 -9.34 -26 -55 -69 -86 -120
Net Income / (Loss) Continuing Operations		 -9.34 -26 -55 -69 -86 -120
Total Pre-Tax Income 		-9.34 -26 -55 -69 -86 -120
Total Operating Income		 -9.30 -26 -59 -80 -104 -133
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 9.30 26 59 80 104 133
Selling, General & Admin Expense		 2.09 5.65 16 17 24 30
Research & Development Expense		 7.20 21 43 63 80 103
Total Other Income / (Expense), net		 -0.04 -0.01 3.60 11 18 13
Interest & Investment Income		 -0.00 0.01 3.65 11 18 13
Basic Earnings per Share		 ($6.05) ($1.91) ($1.32) ($1.62) ($1.51) ($2.01)
Weighted Average Basic Shares Outstanding		 1.54M 13.78M 41.88M 42.70M 57.22M 59.60M
Diluted Earnings per Share		 ($6.05) ($1.91) ($1.32) ($1.62) ($1.51) ($2.01)
Weighted Average Diluted Shares Outstanding		 1.54M 13.78M 41.88M 42.70M 57.22M 59.60M
Weighted Average Basic & Diluted Shares Outstanding		 1.54M 13.78M 42.44M 52.52M 53.09M 53.87M

Quarterly Income Statements for Tyra Biosciences

This table shows Tyra Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -18 -19 -24 -27 -28 -28 -30 -34 -39 -46 -51
Consolidated Net Income / (Loss)		 -18 -19 -24 -26 -28 -28 -30 -34 -39 -46 -51
Net Income / (Loss) Continuing Operations		 -18 -19 -24 -26 -28 -28 -30 -34 -39 -46 -51
Total Pre-Tax Income 		-18 -19 -24 -26 -28 -28 -30 -34 -39 -46 -51
Total Operating Income		 -22 -24 -29 -30 -32 -31 -33 -37 -42 -49 -55
Total Gross Profit		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 22 24 29 30 32 31 33 37 42 49 55
Selling, General & Admin Expense		 5.12 5.54 5.91 7.54 6.89 7.14 7.48 8.33 8.53 9.81 12
Research & Development Expense		 17 18 23 22 25 24 25 28 33 39 43
Total Other Income / (Expense), net		 4.13 4.83 4.59 4.15 3.70 3.35 3.08 2.68 2.69 3.45 3.76
Interest & Investment Income		 4.13 4.83 4.59 4.15 3.70 3.35 3.08 2.68 2.69 3.45 3.76
Basic Earnings per Share		 ($0.35) ($0.32) ($0.41) ($0.43) ($0.47) ($0.47) ($0.50) ($0.57) ($0.64) ($0.69) ($0.74)
Weighted Average Basic Shares Outstanding		 52.23M 58.67M 58.87M 57.22M 59.34M 59.55M 59.67M 59.60M 61.75M 65.99M 69.08M
Diluted Earnings per Share		 ($0.35) ($0.32) ($0.41) ($0.43) ($0.47) ($0.47) ($0.50) ($0.57) ($0.64) ($0.69) ($0.74)
Weighted Average Diluted Shares Outstanding		 52.23M 58.67M 58.87M 57.22M 59.34M 59.55M 59.67M 59.60M 61.75M 65.99M 69.08M
Weighted Average Basic & Diluted Shares Outstanding		 52.54M 52.81M 50.60M 53.09M 53.18M 53.30M 53.37M 53.87M 59.47M 59.68M 69.08M

Annual Cash Flow Statements for Tyra Biosciences

This table details how cash moves in and out of Tyra Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 15 287 -50 -193 34 -15
Net Cash From Operating Activities		 -7.76 -24 -50 -50 -70 -95
Net Cash From Continuing Operating Activities		 -7.76 -24 -50 -50 -70 -95
Net Income / (Loss) Continuing Operations		 -9.34 -26 -55 -69 -86 -120
Consolidated Net Income / (Loss)		 -9.34 -26 -55 -69 -86 -120
Depreciation Expense		 0.05 0.14 0.30 0.36 0.52 0.55
Non-Cash Adjustments To Reconcile Net Income		 0.46 2.89 11 12 17 26
Changes in Operating Assets and Liabilities, net		 1.07 -0.48 -5.85 6.36 -0.73 -1.63
Net Cash From Investing Activities		 -0.31 -0.65 -0.56 -145 -98 72
Net Cash From Continuing Investing Activities		 -0.31 -0.65 -0.56 -145 -98 72
Purchase of Property, Plant & Equipment		 -0.31 -0.66 -0.56 -0.77 -0.66 -0.14
Purchase of Investments		 - - 0.00 -144 -264 -101
Sale and/or Maturity of Investments		 - - 0.00 0.00 166 174
Net Cash From Financing Activities		 23 311 0.63 1.54 202 8.10
Net Cash From Continuing Financing Activities		 23 311 0.63 1.54 202 8.10
Issuance of Common Equity		 0.14 182 0.63 1.54 202 8.10

Quarterly Cash Flow Statements for Tyra Biosciences

This table details how cash moves in and out of Tyra Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 196 -155 4.40 -12 8.76 -2.23 -37 15 7.57 -11 382
Net Cash From Operating Activities		 -22 -10 -18 -20 -25 -24 -22 -24 -33 -31 -32
Net Cash From Continuing Operating Activities		 -22 -10 -18 -20 -25 -24 -22 -24 -33 -31 -32
Net Income / (Loss) Continuing Operations		 -18 -19 -24 -26 -28 -28 -30 -34 -39 -46 -51
Consolidated Net Income / (Loss)		 -18 -19 -24 -26 -28 -28 -30 -34 -39 -46 -51
Depreciation Expense		 0.12 0.13 0.13 0.14 0.14 0.14 0.13 0.13 0.14 0.14 0.13
Non-Cash Adjustments To Reconcile Net Income		 2.89 2.54 5.97 5.52 5.56 5.67 7.16 7.50 7.82 10 12
Changes in Operating Assets and Liabilities, net		 -6.84 5.77 0.02 0.32 -3.01 -1.39 0.20 2.58 -1.23 4.32 6.76
Net Cash From Investing Activities		 18 -145 22 6.96 32 21 -15 34 -120 18 35
Net Cash From Continuing Investing Activities		 18 -145 22 6.96 32 21 -15 34 -120 18 35
Purchase of Property, Plant & Equipment		 -0.14 -0.47 -0.05 -0.01 -0.01 -0.03 -0.04 -0.06 -0.09 -0.07 -0.09
Purchase of Investments		 -12 -177 -36 -38 -6.87 -20 -65 -9.11 -162 -22 -19
Sale and/or Maturity of Investments		 30 33 58 45 39 41 50 44 42 40 54
Net Cash From Financing Activities		 200 0.37 0.74 0.71 2.19 0.58 0.65 4.68 160 2.10 379
Net Cash From Continuing Financing Activities		 200 0.37 0.74 0.71 2.19 0.58 0.65 4.68 160 2.10 379
Issuance of Common Equity		 200 0.37 0.74 0.71 2.19 0.58 0.65 4.68 160 2.10 379

Annual Balance Sheets for Tyra Biosciences

This table presents Tyra Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 16 307 266 226 364 283
Total Current Assets		 15 304 257 212 347 265
Cash & Equivalents		 15 302 251 58 92 77
Short-Term Investments		 - - 0.00 145 249 179
Prepaid Expenses		 0.06 1.88 6.08 8.20 6.02 9.45
Plant, Property, & Equipment, net		 0.30 1.03 1.08 1.63 1.65 1.31
Total Noncurrent Assets		 0.43 1.62 7.82 13 14 16
Other Noncurrent Operating Assets		 0.43 1.62 7.82 13 14 16
Total Liabilities & Shareholders' Equity		 16 307 266 226 364 283
Total Liabilities		 2.00 4.96 8.35 22 20 23
Total Current Liabilities		 1.86 3.62 5.70 15 15 18
Accounts Payable		 0.66 0.60 1.15 4.66 0.59 1.18
Accrued Expenses		 1.05 2.82 4.42 10 14 16
Other Current Liabilities		 0.14 0.20 0.14 0.28 0.41 0.47
Total Noncurrent Liabilities		 0.14 1.35 2.65 6.26 5.81 5.34
Other Noncurrent Operating Liabilities		 0.14 1.35 2.65 6.26 5.81 5.34
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -14 302 258 204 343 259
Total Preferred & Common Equity		 -14 302 258 204 343 259
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -14 302 258 204 343 259
Common Stock		 0.44 342 354 369 594 630
Retained Earnings		 -14 -40 -96 -165 -251 -371
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 0.38 0.77 0.39

Quarterly Balance Sheets for Tyra Biosciences

This table presents Tyra Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets		 250 238 405 392 381 343 321 302 412 383 728
Total Current Assets		 241 225 391 379 366 325 302 281 395 367 712
Cash & Equivalents		 232 216 254 99 104 101 98 62 85 74 456
Short-Term Investments		 - - 128 274 256 218 198 213 299 280 245
Prepaid Expenses		 8.33 8.98 8.32 4.78 5.48 5.62 5.88 6.29 11 13 11
Plant, Property, & Equipment, net		 1.05 1.15 1.59 1.90 1.79 1.52 1.41 1.35 1.22 1.17 1.08
Total Noncurrent Assets		 8.21 13 12 12 13 17 18 19 16 15 15
Other Noncurrent Operating Assets		 8.21 13 12 12 13 17 18 19 16 15 15
Total Liabilities & Shareholders' Equity		 250 238 405 392 381 343 321 302 412 383 728
Total Liabilities		 11 16 15 16 18 20 19 21 24 30 35
Total Current Liabilities		 5.41 10 8.72 10 12 14 14 16 19 25 30
Accounts Payable		 1.44 2.31 2.88 1.58 1.17 2.50 2.25 1.99 3.64 2.33 3.30
Accrued Expenses		 3.82 7.69 5.47 8.42 11 11 11 13 15 22 26
Other Current Liabilities		 0.14 0.15 0.37 0.38 0.40 0.43 0.44 0.46 0.49 0.50 0.52
Total Noncurrent Liabilities		 6.04 6.04 6.15 6.04 5.93 5.70 5.58 5.46 5.21 5.08 4.94
Other Noncurrent Operating Liabilities		 6.04 6.04 6.15 6.04 5.93 5.70 5.58 5.46 5.21 5.08 4.94
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 239 222 390 376 362 324 302 281 388 354 693
Total Preferred & Common Equity		 239 222 390 376 362 324 302 281 388 354 693
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 239 222 390 376 362 324 302 281 388 354 693
Common Stock		 359 364 573 578 586 602 609 617 798 810 1,201
Retained Earnings		 -121 -142 -183 -202 -226 -279 -308 -337 -411 -456 -507
Accumulated Other Comprehensive Income / (Loss)		 - - -0.01 -0.18 1.75 0.69 0.44 0.44 0.11 -0.58 -1.28

Annual Metrics And Ratios for Tyra Biosciences

This table displays calculated financial ratios and metrics derived from Tyra Biosciences' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 41,265,756.00 - - - 53,372,098.00
DEI Adjusted Shares Outstanding		 0.00 41,265,756.00 - - - 53,372,098.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.64 - - - -2.25
Growth Metrics		 - - - - - -
Profitability Metrics		 - - - - - -
Net Operating Profit after Tax (NOPAT)		 -6.51 -18 -41 -56 -73 -93
Return On Investment Capital (ROIC_SIMPLE)		 - - - -27.40% -21.25% -35.86%
Earnings before Interest and Taxes (EBIT)		 -9.34 -26 -59 -80 -104 -133
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.29 -26 -59 -80 -104 -132
Valuation Ratios		 - - - - - -
Leverage & Solvency		 - - - - - -
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -19 -48 -50 -74 -94
Efficiency Ratios		 - - - - - -
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -1.21 -0.45 6.62 0.79 1.71 3.17
Increase / (Decrease) in Invested Capital		 0.00 0.77 7.06 -5.82 0.92 1.46
Book Value per Share		 ($8.84) $7.31 $6.11 $4.74 $6.78 $4.86
Tangible Book Value per Share		 ($8.84) $7.31 $6.11 $4.74 $6.78 $4.86
Total Capital		 14 302 258 204 343 259
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -15 -302 -251 -203 -341 -256
Capital Expenditures (CapEx)		 0.31 0.65 0.56 0.77 0.66 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.80 -1.74 0.37 -7.13 -8.57 -8.65
Debt-free Net Working Capital (DFNWC)		 13 300 252 196 333 247
Net Working Capital (NWC)		 13 300 252 196 333 247
Net Nonoperating Expense (NNE)		 2.83 7.89 14 13 14 27
Net Nonoperating Obligations (NNO)		 -15 -302 -251 -203 -341 -256
Total Depreciation and Amortization (D&A)		 0.05 0.14 0.30 0.36 0.52 0.55
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.91) ($1.32) ($1.62) ($1.51) ($2.01)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 41.60M 41.88M 42.70M 57.22M 59.60M
Adjusted Diluted Earnings per Share		 $0.00 ($1.91) ($1.32) ($1.62) ($1.51) ($2.01)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 41.60M 41.88M 42.70M 57.22M 59.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.91) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 13.78M 42.44M 52.52M 53.09M 53.87M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.51 -18 -41 -56 -73 -93
Debt Service Ratios		 - - - - - -
Payout Ratios		 - - - - - -

Quarterly Metrics And Ratios for Tyra Biosciences

This table displays calculated financial ratios and metrics derived from Tyra Biosciences' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 - - - - 53,089,957.00 53,177,990.00 53,297,140.00 53,372,098.00 53,867,115.00 59,470,381.00 59,676,939.00
DEI Adjusted Shares Outstanding		 - - - - 53,089,957.00 53,177,990.00 53,297,140.00 53,372,098.00 53,867,115.00 59,470,381.00 59,676,939.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - -0.53 -0.53 -0.56 -0.63 -0.73 -0.77 -0.86
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Growth		 -55.78% -46.98% -19.25% -15.84% -42.82% -33.78% -15.23% - -32.02% -56.06% -66.87%
EBIT Growth		 -55.73% -46.95% -19.37% -15.94% -42.68% -33.66% -15.17% - -31.86% -55.80% -66.60%
NOPAT Growth		 -55.73% -46.95% -19.37% -15.94% -42.68% -33.66% -15.17% - -31.86% -55.80% -66.60%
Net Income Growth		 -53.13% -40.91% -13.54% -12.01% -54.72% -50.24% -24.37% - -39.64% -62.14% -71.16%
EPS Growth		 -25.00% -3.23% 16.33% 20.37% -34.29% -46.88% -21.95% - -36.17% -46.81% -48.00%
Operating Cash Flow Growth		 -123.70% -6.69% -4.39% -44.77% -15.57% -130.84% -25.04% - -27.94% -31.23% -43.93%
Free Cash Flow Firm Growth		 13.47% 7.80% 16.45% -79.20% -22.04% -104.18% -69.11% - -48.53% -9.75% 5.12%
Invested Capital Growth		 4.63% -63.52% -66.89% 115.64% -38.10% 161.50% 158.80% - -10.50% -104.77% -237.94%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 13.05% -5.43% -21.67% -3.86% -7.21% 1.25% -4.79% - -15.05% -16.73% -12.05%
EBIT Q/Q Growth		 12.92% -5.42% -21.55% -3.90% -7.17% 1.25% -4.74% - -15.01% -16.68% -12.00%
NOPAT Q/Q Growth		 12.92% -5.42% -21.55% -3.90% -7.17% 1.25% -4.74% - -15.01% -16.68% -12.00%
Net Income Q/Q Growth		 20.32% -2.80% -28.41% -6.47% -10.07% 0.17% -6.30% - -16.17% -15.91% -12.21%
EPS Q/Q Growth		 35.19% 8.57% -28.13% -4.88% -9.30% 0.00% -6.38% - -12.28% -7.81% -7.25%
Operating Cash Flow Q/Q Growth		 -62.78% 53.43% -74.48% -9.45% -29.95% 6.98% 5.49% - -37.87% 4.59% -3.65%
Free Cash Flow Firm Q/Q Growth		 -31.62% 21.27% -24.70% -38.67% 10.37% -31.72% -3.28% - -7.00% 2.66% 10.71%
Invested Capital Q/Q Growth		 835.31% -69.70% -3.96% -20.76% 168.48% 27.99% -4.95% - 29.46% -106.81% -2,651.43%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Interest Burden Percent		 81.50% 79.47% 83.96% 86.04% 88.37% 89.34% 90.66% - 93.59% 92.97% 93.14%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -23.63% -26.32% -28.66% -31.60% -27.04% -31.21% -34.75% - -36.87% -45.31% -34.89%
Cash Return on Invested Capital (CROIC)		 -853.18% -1,496.64% -1,514.62% -5,900.19% -1,278.61% -2,185.56% -2,366.07% - -2,288.62% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -23.63% -26.32% -28.66% -31.60% -27.04% -31.21% -34.75% - -36.87% -45.31% -34.89%
Return on Equity Simple (ROE_SIMPLE)		 -19.35% -21.51% -23.11% 0.00% -29.81% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -16 -16 -20 -21 -22 -22 -23 -26 -29 -34 -38
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -0.82% -0.74% -1.39% -1.75% -1.67% -1.82% -2.14% - -2.82% -3.46% -2.60%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -6.06% -6.89% -7.29% -8.22% -9.86% -7.59% -9.70% -5.55%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -22 -24 -29 -30 -32 -31 -33 -37 -42 -49 -55
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -22 -23 -28 -30 -32 -31 -33 -36 -42 -49 -55
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.21 2.23 3.43 2.05 1.53 1.68 2.66 - 5.32 5.37 1.88
Price to Tangible Book Value (P/TBV)		 2.21 2.23 3.43 2.05 1.53 1.68 2.66 - 5.32 5.37 1.88
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 64.57 207.53 408.41 211.66 38.07 36.19 84.28 - 408.77 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Financial Leverage		 -0.98 -0.99 -0.99 -1.00 -0.98 -0.99 -0.99 - -0.99 -0.99 -1.00
Leverage Ratio		 1.03 1.05 1.06 1.08 1.05 1.05 1.06 - 1.06 1.07 1.06
Compound Leverage Factor		 0.84 0.83 0.89 0.93 0.93 0.94 0.96 - 0.99 1.00 0.99
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Altman Z-Score		 35.09 30.91 40.73 20.54 14.49 15.19 20.09 - 49.96 37.36 22.48
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 44.83 36.46 29.55 23.81 22.78 21.94 17.71 - 20.49 14.91 23.93
Quick Ratio		 43.88 36.00 29.11 23.40 22.39 21.52 17.31 - 19.91 14.38 23.56
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -16 -13 -16 -22 -19 -26 -26 -27 -29 -28 -25
Operating Cash Flow to CapEx		 -16,197.06% -2,182.55% -34,419.23% -326,500.00% -181,842.86% -76,387.10% -57,384.62% - -37,012.50% -47,084.85% -35,790.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 7.42 2.25 2.16 1.71 4.59 5.88 5.59 3.17 4.11 -0.28 -7.70
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.33 -3.91 -4.36 0.92 -2.83 3.63 3.43 1.46 -0.48 -6.16 -13
Enterprise Value (EV)		 479 466 881 362 175 213 471 - 1,680 1,546 605
Market Capitalization		 861 840 1,241 703 494 509 746 - 2,063 1,899 1,305
Book Value per Share		 $7.42 $7.16 $6.86 $6.78 $6.09 $5.68 $5.26 $4.86 $7.20 $5.95 $11.61
Tangible Book Value per Share		 $7.42 $7.16 $6.86 $6.78 $6.09 $5.68 $5.26 $4.86 $7.20 $5.95 $11.61
Total Capital		 390 376 362 343 324 302 281 259 388 354 693
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -382 -374 -360 -341 -319 -296 -275 -256 -383 -354 -701
Capital Expenditures (CapEx)		 0.14 0.47 0.05 0.01 0.01 0.03 0.04 0.06 0.09 0.07 0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.40 -5.60 -6.89 -8.57 -8.62 -7.89 -9.59 -8.65 -8.11 -12 -19
Debt-free Net Working Capital (DFNWC)		 382 368 353 333 310 288 265 247 375 342 682
Net Working Capital (NWC)		 382 368 353 333 310 288 265 247 375 342 682
Net Nonoperating Expense (NNE)		 2.57 2.23 3.99 4.77 5.85 6.08 6.81 8.27 9.91 11 13
Net Nonoperating Obligations (NNO)		 -382 -374 -360 -341 -319 -296 -275 -256 -383 -354 -701
Total Depreciation and Amortization (D&A)		 0.12 0.13 0.13 0.14 0.14 0.14 0.13 0.13 0.14 0.14 0.13
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.35) ($0.32) ($0.41) ($0.43) ($0.47) ($0.47) ($0.50) ($0.57) ($0.64) ($0.69) ($0.74)
Adjusted Weighted Average Basic Shares Outstanding		 52.23M 58.67M 58.87M 57.22M 59.34M 59.55M 59.67M 59.60M 61.75M 65.99M 69.08M
Adjusted Diluted Earnings per Share		 ($0.35) ($0.32) ($0.41) ($0.43) ($0.47) ($0.47) ($0.50) ($0.57) ($0.64) ($0.69) ($0.74)
Adjusted Weighted Average Diluted Shares Outstanding		 52.23M 58.67M 58.87M 57.22M 59.34M 59.55M 59.67M 59.60M 61.75M 65.99M 69.08M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 52.54M 52.81M 50.60M 53.09M 53.18M 53.30M 53.37M 53.87M 59.47M 59.68M 69.08M
Normalized Net Operating Profit after Tax (NOPAT)		 -16 -16 -20 -21 -22 -22 -23 -26 -29 -34 -38
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Tyra Biosciences remains a development-stage biotechnology company with no reported revenue in the periods provided. Its financial profile is therefore driven primarily by research spending, clinical-development progress, equity financing and investment income rather than product sales.

  • Strong liquidity position: As of June 30, 2026, Tyra had $73.8 million in cash and equivalents plus $280.1 million in short-term investments, or approximately $353.5 million in readily available funds. This compares with roughly $296.3 million at June 30, 2025.
  • Low balance-sheet leverage: Total liabilities were $29.7 million versus $353.7 million of equity in Q2 2026. The company has no preferred stock and reported no commitments or contingencies in the provided balance sheets, reducing near-term financial leverage risk.
  • Potential cash runway: Q2 operating cash use was $31.1 million. Holding that quarterly burn rate constant, cash and short-term investments would cover approximately 11 quarters of operating needs, although rising research spending could shorten the runway.
  • Investment income provides some support: Interest and investment income increased to $3.4 million in Q2 2026 from $2.7 million in Q2 2025. The company’s sizable investment portfolio helps offset a portion of its operating losses.
  • Research investment is expanding: Research and development expense rose from $24.3 million in Q2 2024 to $39.2 million in Q2 2026. For a clinical-stage biotechnology company, higher R&D spending may support advancement of its drug pipeline, although it has not yet produced revenue.
  • Assets remain concentrated in financial investments: Short-term investments represented about 73% of total assets at June 30, 2026. This provides liquidity, but investment income and reported cash balances may fluctuate with interest rates and portfolio activity.
  • Losses are widening: Quarterly net loss increased from $12.5 million in Q3 2022 to $45.6 million in Q2 2026. The Q2 2026 loss was also larger than the $39.3 million loss in Q1 2026 and the $33.8 million loss in Q4 2025.
  • Operating expenses are accelerating: Total operating expenses reached $49.0 million in Q2 2026, up from $31.9 million in Q1 2024 and $14.3 million in Q1 2023. SG&A also rose to $9.8 million in Q2 2026 from $5.1 million in Q1 2023.
  • Operating cash burn is increasing: Net cash used in operating activities was $31.1 million in Q2 2026, compared with $25.5 million in Q1 2024 and $9.8 million in Q1 2023. Tyra has generated negative operating cash flow in every quarter supplied.
  • Shareholder dilution remains a risk: Weighted-average basic shares outstanding increased from 42.4 million in Q1 2023 to 66.0 million in Q2 2026. The company raised $160.4 million through common-equity issuance in Q1 2026, indicating that future capital needs could continue to dilute existing shareholders.

Overall, Tyra’s balance sheet is currently well funded and lightly leveraged, but the company remains dependent on its cash and investment portfolio because revenue is absent and operating losses are growing. Investors should closely monitor clinical progress, quarterly cash burn, R&D efficiency and whether additional equity financing becomes necessary.

11/10/26 06:58 PM ETAI Generated. May Contain Errors.

Tyra Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Tyra Biosciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Tyra Biosciences' net income appears to be on a downward trend, with a most recent value of -$119.95 million in 2025, falling from -$9.34 million in 2020. The previous period was -$86.48 million in 2024. Find out what analysts predict for Tyra Biosciences in the coming months.

Tyra Biosciences' total operating income in 2025 was -$132.76 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $132.76 million

Over the last 5 years, Tyra Biosciences' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

In the past 13 quarters, Tyra Biosciences' cash and equivalents has ranged from $61.95 million in Q3 2025 to $456.02 million in Q3 2026, and is currently $456.02 million as of their latest financial filing in Q3 2026.

Tyra Biosciences had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2020.

Over the last 5 years, Tyra Biosciences' book value per share changed from -8.84 in 2020 to 4.86 in 2025.


Related Companies

Financial statements for NASDAQ:TYRA last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Black Friday Bombshell (for traders)
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...
Behind the Markets | Sponsoredtc pixel
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...
Weiss Ratings | Sponsoredtc pixel
What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...
Porter & Company | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
It’s now or never
Anthropic's Claude now generates more revenue than ChatGPT, and the company is about to go public at a $1.5 tr...
Paradigm Press | Sponsoredtc pixel
The One AI Stock to Watch in 2027
In 2019, Charles Mizrahi named Marvell Technology his top AI pick. It's since climbed 700 percent. Now he's...
Prosperity Research | Sponsoredtc pixel
Have You Heard of Tokenized Gold?
$1.6 billion has already moved into tokenized gold, and BlackRock CEO Larry Fink wants to tokenize $110 trilli...
Decentralized Masters | Sponsoredtc pixel